Most GLP1 Wegovy (semaglutide) and GIP Mounjaro (tirzepatide) medications share similar side effects because they work in the same way
In the diabetes group, patients on semaglutide had a fourfold increased risk of NAION compared to those on other treatments
Research has identified several key risk factors that require special consideration: Gastrointestinal Disorders: History of gastroparesis or delayed gastric emptying Inflammatory bowel disease Previous gastric surgery Chronic acid reflux or GERD Metabolic Conditions: Type 1 or Type 2 diabetes History of hypoglycemic episodes Thyroid disorders Adrenal insufficiency Cardiovascular Risk Factors: Existing heart rhythm disorders Uncontrolled hypertension History of cardiovascular events Researchers with these conditions should work closely with healthcare providers and consider starting with lower doses
Evidence, Risks, and Guidance Retatrutide and depression is an important question as this investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors advances through clinical trials for obesity and type 2 diabetes
This is part of the reason that Melanotan may aid fat burning
Dihexa, a novel synaptogenic compound, enhances cognitive function in animal models of Alzheimer's disease